Company Description
CoLabs Int’l is an over-the-counter pharmaceutical company with multi-market applications for our revolutionary targeted drug delivery system which is identified as QuantaSphere® Technology.
We currently hold 29 issued patents and have an additional 15 patent applications pending. Our technology places OTC drugs, pharmaceuticals, and chemicals into micro-sized, electrostatically charged encapsulates as well as into other types of micro-encapsulates.
These encapsulates are then suspended in uniquely designed formulations. This formulation of a highly advanced micro-technology can: target the delivery of topically applied drugs; limit unwanted absorption of chemicals, drugs, and cosmetics through the skin; and provide a designed release of active ingredients with a prescribed depth of skin penetration.
We have already developed commercially unique and innovative targeted skin delivery systems for topical pharmacology.
Our technology limits unwanted side effects that can occur as a result of uncontrolled absorption of topical medications through the skin.
Our current applications include anti-bacterial/viral sanitizers/soaps, sunscreens, pest-repellents, and healing cosmetic lotions.
| Country | United States |
| Founded | 2008 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 4 |
| CEO | Laura Cohen |
Contact Details
Address: 18593 Main St. Huntington Beach, CA 92648 United States | |
| Phone | 949-945-3330 |
| Website | colabsintl.com |
Stock Details
| Ticker Symbol | CLLB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $4.50 |
| CIK Code | 0001584879 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Laura Cohen | Chief Executive Officer and Chairman of our Board of Directors |
| Lisa LeBlanc | President and Director |
| William Cohen | Chief Financial Officer and Chief Development Officer |
| Daniel Traynor | Vice President of Product Development |
| Charles Fritts, Esq. | Director |
| Dean Stathakis, Esq. | Director |
| Peter Barton Hutt, Esq. | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Feb 1, 2024 | RW | Filing |
| Jun 2, 2023 | D/A | Filing |
| Mar 27, 2023 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Feb 24, 2023 | D | Notice of Exempt Offering of Securities |
| Dec 29, 2022 | 1-K/A | Filing |
| Dec 20, 2022 | 1-U | Current Report Pursuant to Regulation A |
| Oct 7, 2022 | 1-K | Acc-no: 0001493152-22-011625 (33 Act) |
| Oct 7, 2022 | 1-SA | Filing |
| Jul 13, 2022 | 1-Z | Filing |
| Oct 25, 2021 | 1-U | Current Report Pursuant to Regulation A |